{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["15(4)"],"submitter":["Lhermitte B"],"pubmed_abstract":["Over the last few decades, deciphering the alteration of molecular pathways in brain tumors has led to impressive changes in diagnostic refinement. Among the molecular abnormalities triggering and/or driving gliomas, alterations in the MAPK pathway reign supreme in the pediatric population, as it is encountered in almost all low-grade pediatric gliomas. Activating abnormalities in the MAPK pathway are also present in both pediatric and adult high-grade gliomas. Across those alterations, <i>BRAF</i> p.V600E mutations seem to define homogeneous groups of tumors in terms of prognosis. The recent development of small molecules inhibiting this pathway retains the attention of neurooncologists on BRAF-altered tumors, as conventional therapies showed no significant effect, nor prolonged efficiency on the high-grade or low-grade unresectable forms. Nevertheless, tumoral heterogeneity and especially molecular alteration(s) associated with MAPK-pathway abnormalities are not fully understood with respect to how they might lead to the specific dismal prognosis of those gliomas and/or affect their response to targeted therapies. This review is an attempt to provide comprehensive information regarding molecular alterations related to the aggressiveness modulation in <i>BRAF</i>-mutated gliomas and the current knowledge on how to use those targeted therapies in such situations."],"journal":["Cancers"],"pagination":["1268"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9954401"],"repository":["biostudies-literature"],"pubmed_title":["Molecular Heterogeneity in BRAF-Mutant Gliomas: Diagnostic, Prognostic, and Therapeutic Implications."],"pmcid":["PMC9954401"],"pubmed_authors":["Dontenwill M","Wolf T","Hirsch E","Chammas A","Todeschi J","Noel G","Lhermitte B","Reita D","Salmon A","Coca A","Guerin E","Chenard MP","Proust F","Schott R","Martin S","Entz-Werle N"],"additional_accession":[]},"is_claimable":false,"name":"Molecular Heterogeneity in BRAF-Mutant Gliomas: Diagnostic, Prognostic, and Therapeutic Implications.","description":"Over the last few decades, deciphering the alteration of molecular pathways in brain tumors has led to impressive changes in diagnostic refinement. Among the molecular abnormalities triggering and/or driving gliomas, alterations in the MAPK pathway reign supreme in the pediatric population, as it is encountered in almost all low-grade pediatric gliomas. Activating abnormalities in the MAPK pathway are also present in both pediatric and adult high-grade gliomas. Across those alterations, <i>BRAF</i> p.V600E mutations seem to define homogeneous groups of tumors in terms of prognosis. The recent development of small molecules inhibiting this pathway retains the attention of neurooncologists on BRAF-altered tumors, as conventional therapies showed no significant effect, nor prolonged efficiency on the high-grade or low-grade unresectable forms. Nevertheless, tumoral heterogeneity and especially molecular alteration(s) associated with MAPK-pathway abnormalities are not fully understood with respect to how they might lead to the specific dismal prognosis of those gliomas and/or affect their response to targeted therapies. This review is an attempt to provide comprehensive information regarding molecular alterations related to the aggressiveness modulation in <i>BRAF</i>-mutated gliomas and the current knowledge on how to use those targeted therapies in such situations.","dates":{"release":"2023-01-01T00:00:00Z","publication":"2023 Feb","modification":"2025-04-05T07:24:29.12Z","creation":"2025-04-05T07:24:29.12Z"},"accession":"S-EPMC9954401","cross_references":{"pubmed":["36831610"],"doi":["10.3390/cancers15041268"]}}